title: Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: results of a prematurely closed phase 2 study.
authors.affiliation: a III. Medical Department, Technische Universität München , Munich , Germany.
authors.forename: Susanne
authors.initials: S
authors.lastname: Schreiber
authors.affiliation: a III. Medical Department, Technische Universität München , Munich , Germany.
authors.forename: Alexander
authors.initials: A
authors.lastname: Hoellein
authors.affiliation: b Onkologie Ravensburg , Ravensburg , Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Decker
authors.affiliation: a III. Medical Department, Technische Universität München , Munich , Germany.
authors.forename: Stefanie
authors.initials: S
authors.lastname: Jilg
authors.affiliation: c Medical Department III , Ludwig-Maximilians-Universität München , Munich , Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Dreyling
authors.affiliation: a III. Medical Department, Technische Universität München , Munich , Germany.
authors.forename: Christian
authors.initials: C
authors.lastname: Peschel
authors.affiliation: a III. Medical Department, Technische Universität München , Munich , Germany.
authors.forename: Ulrich
authors.initials: U
authors.lastname: Keller
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D000068338:Everolimus / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D020522:Lymphoma, Mantle-Cell / Q000188:drug therapy* / Q000401:mortality / Q000473:pathology; D060046:Maintenance Chemotherapy; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D000068338:Everolimus